Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
DBVT (NYSE Euronext Paris) reports the total number of shares and voting rights as of March 31, 2026 under Article 223-16 of the AMF General Regulations. The company has 296,042,447 total shares and a gross total of voting rights of 296,042,447.
The net total of voting rights (excluding shares without voting rights) is 295,914,379. ISIN: FR0010417345. A PDF attachment is available for the detailed notice.
DBV Technologies (Nasdaq: DBVT) announced it filed its 2025 Annual Report on Form 10-K with the SEC and its 2025 Universal Registration Document (2025 URD) with the AMF on March 26, 2026.
The 2025 URD includes the annual financial report, the Board of Directors' corporate governance report under Article L.225-37, the description of the share buy-back program, statutory auditor reports, and auditor fees. Documents are available on the company website, the SEC site, and the AMF site.
DBV Technologies (Nasdaq: DBVT) reported full year 2025 results and a business update focused on advancing VIASKIN® Peanut Patch clinical programs for ages 1–7 and preparing for BLA submissions.
Key facts: positive Phase 3 VITESSE topline, 2025 PIPE and ATM financings, $194.2M cash at 12/31/2025 plus $94M received January 2026, and cash runway into Q2 2027.
DBV Technologies (Euronext: DBV; Nasdaq: DBVT) will join the CAC Mid 60 and SBF 120 indices following Euronext Paris's annual review. The Scientific Council admitted DBV on March 12, 2026, and the index changes took effect on March 23, 2026.
The company said inclusion should boost visibility with French and European investors as it advances toward commercialization and continued development in food allergy therapies.
DBV Technologies (Nasdaq: DBVT) will participate in two investor events in March 2026: a fireside chat at Citizens Life Sciences Conference on March 10, 2026 at 1:40pm ET and one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026.
The Citizens presentation will be webcast live and a replay will be available on the company's Events page 90 days after the event.
DBVT (DBVT) reports the total number of shares and voting rights as of February 28, 2026 under Article 223-16 of the AMF General Regulations. The company lists 278,352,082 total shares and a total gross voting rights count of 278,352,082.
The total net voting rights (excluding shares without voting rights) is 278,236,200. Market: NYSE Euronext Paris. ISIN: FR0010417345.
DBV Technologies (Nasdaq:DBVT) reported additional positive data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch at AAAAI 2026. The trial met its primary endpoint: 46.6% responders on VIASKIN versus 14.8% on placebo (difference 31.8%, p<0.001).
Additional highlights: 82.8% increased eliciting dose by ≥1 step, 60.1% by ≥2 steps, low serious safety signals, and a planned Biologics License Application submission to FDA in H1 2026.
DBV Technologies (Nasdaq: DBVT) will present additional data from the positive VITESSE Phase 3 study of the VIASKIN Peanut Patch in children ages 4–7 at the AAAAI 2026 Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026.
An oral abstract presentation is scheduled for Feb 28, 2:15–2:25pm ET, with a product theater on Feb 28, 10:00–10:30am ET featuring panelists discussing epicutaneous immunotherapy (EPIT) and early intervention. DBV will also exhibit at booth #1527.
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit in New York on February 12, 2026 at 2:30pm ET. A live webcast will be available and a replay will remain on the company site for 90 days.
Investors can access the live webcast via the company’s Events page and view the replay through the investor website.
DBVT (NYSE Euronext Paris) disclosed its total shares and voting rights as of January 31, 2026 under Article 223-16 of the AMF General Regulations.
The company reported 274,852,082 total shares and a gross total of 274,852,082 voting rights, with a net total of 274,792,237 voting rights (excluding shares without voting rights).